Overview
Areas of Research/Interest
- Optimizing biomarker directed treatment for late-stage lung cancer
- Optimizing treatment for patients with lung cancer and brain metastases
- Finding novel targets in early and advanced stage lung cancer
- Optimizing access to health care in women and minorities facing lung cancer
Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action.
Journal article Lung Cancer · April 2026 Brain metastases (BM) occur in 30-50% of non-small cell lung cancer (NSCLC) and up to 80% of small cell lung cancer (SCLC) patients, yet historically over 80% of clinical trials excluded this population. Current eligibility requirements often mandate compl ... Full text Link to item CiteCRE26-055: A Novel Case of Immune Checkpoint Inhibitor-Mediated DAT-Negative Autoimmune Hemolytic Anemia.
Journal article J Natl Compr Canc Netw · March 31, 2026 Full text Link to item CiteCRE26-055: A Novel Case of Immune Checkpoint Inhibitor-Mediated DAT-Negative Autoimmune Hemolytic Anemia.
Journal article J Natl Compr Canc Netw · March 31, 2026 Full text Link to item CiteRecent Grants
A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients with SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Plexium, Inc. · 2026 - 2031An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Clinical TrialPrincipal Investigator · Awarded by Henlius USA Inc. · 2025 - 2030A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations
Clinical TrialPrincipal Investigator · Awarded by Iambic Therapeutics, Inc. · 2025 - 2030View All Grants
Education
University of Queensland (Australia) ·
2017
M.D.